Given the complex interplay within the TME and its influence on DLBCL progression and drug resistance, understanding the role of M2 CD163-positive TAMs could lead to the identification of novel biomarkers and therapeutic targets, potentially transforming DLBCL management and improving patient outcomes. The gene discussed is CD163; the disease is diffuse large B-cell lymphoma.